Jazz Pharmaceuticals (NASDAQ:JAZZ) updated its FY 2021
After-Hours earnings guidance on Tuesday. The company provided earnings per share guidance of 15.65-16.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.78. The company issued revenue guidance of $2.55-2.7 billion, compared to the consensus revenue estimate of $2.56 billion.
A number of research analysts have issued reports on the company. Morgan Stanley cut Jazz Pharmaceuticals from an overweight rating to an equal weight rating and decreased their target price for the company from $177.00 to $162.00 in a research report on Friday, January 29th. Barclays lifted their target price on Jazz Pharmaceuticals from $225.00 to $233.00 and gave the company an overweight rating in a research report on Tuesday, November 3rd. Wells Fargo & Company lifted their target price on Jazz Pharmaceuticals from $171.00 to $184.00 and gave the company an overweight rating in a research report on Tuesday, November 3rd. UBS Group started coverage on Jazz Pharmaceuticals in a report on Tuesday, December 15th. They set a buy rating and a $174.00 price target on the stock. Finally, Zacks Investment Research cut Jazz Pharmaceuticals from a hold rating to a strong sell rating and set a $142.00 price target on the stock. in a report on Wednesday, February 10th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and sixteen have given a buy rating to the stock. Jazz Pharmaceuticals has an average rating of Buy and a consensus price target of $173.74.
Shares of Jazz Pharmaceuticals stock traded down $4.21 during midday trading on Tuesday, reaching $157.47. The company had a trading volume of 684,451 shares, compared to its average volume of 823,635. The stock has a fifty day moving average price of $162.94 and a 200 day moving average price of $148.14. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.98 and a quick ratio of 3.84. The firm has a market cap of $8.77 billion, a PE ratio of 49.86, a P/E/G ratio of 4.64 and a beta of 1.08. Jazz Pharmaceuticals has a fifty-two week low of $86.88 and a fifty-two week high of $172.67.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 7,950 shares of the business’s stock in a transaction that occurred on Monday, January 4th. The stock was sold at an average price of $162.01, for a total value of $1,287,979.50. Following the transaction, the chief executive officer now directly owns 319,532 shares of the company’s stock, valued at $51,767,379.32. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 1st. The shares were sold at an average price of $140.58, for a total value of $140,580.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,762 shares of company stock worth $1,710,703. Insiders own 4.60% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.
Featured Story: What is a bull market?
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.